- $156.05m
- $102.51m
- $42.17m
Coherus BioSciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Coherus Biosciences Increases Size Of Board From Nine Directors To Ten
Brief: Coherus Announces U.S. Launch Of UDENYCA ONBODY
KKR to acquire a stake in health tech firm Cotiviti
Brief: Coherus Amends Term Loan Agreement With Pharmakon Advisors
U.S. RESEARCH ROUNDUP-Meta Platforms, Qualcomm, Visa
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
Coherus gains on eye drug sale to Sandoz for $170 mln
U.S. STOCKS ON THE MOVE-Ionis Pharma, Sagimet Biosciences, Fastly
U.S. STOCKS ON THE MOVE-B. Riley, Boeing, Archer-Daniels-Midland
Coherus gains after selling eye drug to Sandoz for $170 mln
Sandoz to buy eye drug Cimerli in $170 million deal (updated)
U.S. STOCKS ON THE MOVE-SciSparc, Teekay Tankers
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Ally Financial, Modular Medical
U.S. STOCKS ON THE MOVE-IBM, Wayfair, Netflix
U.S. STOCKS ON THE MOVE-Super Micro Computer, Coherus, Travelers Companies
Coherus rises after liver cancer treatment shows promise in mid-stage study
Brief: Coherus Presents Positive Phase 2 Clinical Data On Casdozokitug
Coherus falls after ending licensing deal with Junshi, 2023 revenue view